# ScoreItem: ECG - Sokolow-Lyon (S V1 + R V5/V6)

**ID:** `019bf31d-2ef0-7c5b-bea0-13bf3f2a4fbb`
**FullName:** ECG - Sokolow-Lyon (S V1 + R V5/V6) (Exames - Imagem)
**Unit:** mm

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 14 artigos
- Avg Similarity: 0.526

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7c5b-bea0-13bf3f2a4fbb`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7c5b-bea0-13bf3f2a4fbb",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** ECG - Sokolow-Lyon (S V1 + R V5/V6) (Exames - Imagem)
**Unidade:** mm

**30 chunks de 14 artigos (avg similarity: 0.526)**

### Chunk 1/30
**Article:** Predictive value of electrocardiographic left ventricular hypertrophy in the general population: A meta-analysis (2020)
**Journal:** Journal of Electrocardiology
**Section:** abstract | **Similarity:** 0.665

This meta-analysis examined electrocardiographic left ventricular hypertrophy (LVH) as a predictor of adverse cardiac outcomes in 58,400 participants across 10 studies. The Sokolow-Lyon voltage, Cornell voltage, and Cornell product criteria showed comparable ability in predicting major adverse cardiovascular events (MACE), with risk ratios ranging from 1.56 to 1.70. The pooled risk ratio of MACE was 1.62 (95% CI 1.40-1.89) for Sokolow-Lyon voltage criteria. The pooled risk ratio of all-cause mortality was 1.47 (95% CI 1.10-1.97), and cardiovascular mortality was 1.38 (95% CI 1.19-1.60) for Sokolow-Lyon criteria. Cornell voltage demonstrated stronger predictive value for cardiovascular and all-cause mortality outcomes.

---

### Chunk 2/30
**Article:** Left ventricular hypertrophy determined by Sokolow-Lyon criteria: a different predictor in women than in men? (2006)
**Journal:** Journal of Human Hypertension
**Section:** abstract | **Similarity:** 0.624

This prospective study examined 3,338 women and 3,330 men with hypertension over 11.2 years to assess whether ECG left ventricular hypertrophy (LVH) by Sokolow-Lyon voltage criteria predicted cardiovascular outcomes differently by gender. Increasing voltage independently predicted CVD mortality in both men and women. The risk of stroke, coronary heart disease (CHD) and cardiovascular disease (CVD) mortality increased significantly for each quantitative 0.1 mV increase in baseline ECG voltage, in women within the range of 1.6-3.9% and in men 1.4-3.0%. Women tended to have a high risk of stroke mortality owing to LVH, while men demonstrated stronger associations between voltage and coronary heart disease mortality.

---

### Chunk 3/30
**Article:** Hipertensão Arterial Sistêmica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.543

causa secundária identificável.
**O diagnóstico e a classificação da hipertensão seguem limiares específicos que variam conforme o método de medição, com estágios progressivos que orientam a terapia.**
- A pressão arterial é classificada como ótima (abaixo de 120/80 mmHg), normal (até 129/84 mmHg) e pré-hipertensão (130-139 / 85-89 mmHg).
- O diagnóstico de hipertensão é estabelecido a partir de 14 por 9 mmHg em medições de consultório, aplicável a indivíduos com mais de 18 anos.
- Os estágios da hipertensão são definidos como: Estágio 1 (a partir de 14/9), Estágio 2 (a partir de 16/10) e Estágio 3 (acima de 18/11).
- Para exames fora do consultório, os limiares são mais baixos: 13 por 8 mmHg para o MAPA (24 horas) e 13 por 8,5 mmHg para o MRPA.

---

### Chunk 4/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.540

dade, inatividade física, pressão arterial e dislipidemia.
- A inflamação é indicada por marcadores como a Proteína C-Reativa (PCR), onde um valor de 5 já é considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamatória é medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso é um risco) e um exemplo de paciente com 6.44.
- A saúde do endotélio é avaliada pelo óxido nítrico, que deve estar em 8.8; um paciente com 4.8 já apresenta disfunção sistêmica.
- A LDL oxidada é um marcador crítico, com um limite saudável de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco parâmetros clássicos para definir a síndrome metabólica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, é de 50.

---

### Chunk 5/30
**Article:** Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography (2015)
**Journal:** Journal of the American Society of Echocardiography
**Section:** abstract | **Similarity:** 0.538

Updated guidelines for echocardiographic assessment. Normal LVEF ≥54% in women by Simpson method. Sex-specific reference ranges are essential for accurate diagnosis of systolic dysfunction.

---

### Chunk 6/30
**Article:** Hipertensão Arterial Sistêmica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.536

*Classes Preferenciais:** IECA (Inibidores da Enzima Conversora de Angiotensina), BRA (Bloqueadores do Receptor de Angiotensina), diuréticos tiazídicos e bloqueadores do canal de cálcio. A combinação entre eles é a melhor estratégia. A associação de IECA com BRA é proibida.
*   **Hierarquia Terapêutica:**
    1.  Mudança de estilo de vida.
    2.  IECA/BRA, bloqueador de canal de cálcio ou diurético tiazídico.
    3.  Espironolactona (4ª opção).
    4.  Betabloqueador (5ª opção).
*   **Betabloqueadores:** Não são mais primeira linha. Têm menor proteção cardiovascular, aumentam o risco de diabetes e causam efeitos adversos (disfunção sexual, ganho de peso). São considerados remédios de exceção.
*   **Metas Terapêuticas:**
    *   **Alto risco:** Manter PA entre 120/70 e 130/80 mmHg.
    *   **Baixo/moderado risco e idosos hígidos:** Manter PA até 140/90 mmHg.

---

### Chunk 7/30
**Article:** Aula Afonso Salgado - Sistema nervoso autônomo (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.536

iação descrito inclui:

- Exame realizado preferencialmente pela manhã, em jejum, evitando a ingestão de medicamentos naquele momento (pois alteram a leitura).  
- Repetição do exame em **3 a 5 ocasiões** em condições semelhantes, para obter dados de “padrão ouro” (maior confiabilidade).  

A partir do ECG, softwares especializados analisam a VFC tanto no **domínio do tempo** quanto no **domínio da frequência**:

- No domínio do tempo, o parâmetro mais citado é o **SDNN** (desvio padrão dos intervalos NN), que é uma raiz quadrada aplicada à distribuição dos intervalos.  
- SDNN mais alto indica maior variabilidade; SDNN baixo indica rigidez do ritmo, associada a pior prognóstico.

No domínio da frequência, embora Afonso não detalhe numericamente, ele indica o uso de técnicas matemáticas como:

- **Rápida transformada de Fourier (FFT)**,  
- **wavelet transform**,  
- **ritmogramas** (conceito de origem russa).

---

### Chunk 8/30
**Article:** Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista não identificada
**Section:** results | **Similarity:** 0.535

diseasedurationandlowdensitylipoproteincholesterollevels.JAmCollCardiol
1996:28:573–579.50Pedersen&Saltin
	
	
Getulio José Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

CoakleyEH,RimmEB,ColditzG,KawachiI,WillettW.Predictorsofweightchangeinmen:resultsfrom
theHealthProfessionalsFollow-upStudy.IntJObesRelatMetabDisord1998:22:89–96.CoatsAJ,AdamopoulosS,MeyerTE,ConwayJ,SleightP.Effectsofphysicaltraininginchronicheartfailure.Lancet1990:335:63–66.CoatsAJ,AdamopoulosS,RadaelliA,McCanceA,MeyerTE,BernardiL,SoldaPL,DaveyP,OrmerodO,ForfarC.Controlledtrialofphysical
traininginchronicheartfailure.

---

### Chunk 9/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista não identificada
**Section:** results | **Similarity:** 0.534

atherosclerosis:Resultsfromaprospective,parallel-groupcohortstudy.Clin.Chim.Acta2015,447,16–22.[CrossRef]101.Hijazi,Z.;Lindahl,B.;Oldgren,J.;Andersson,U.;Lindbäck,J.;Granger,C.B.;Alexander,J.H.;Gersh,B.J.;Hanna,M.;Harjola,V.;etal.RepeatedMeasurementsofCardiacBiomarkersinAtrialFibrillationandValidationoftheABCStrokeScoreOverTime.J.Am.HeartAssoc.2017,6,e004851.[CrossRef]102.Abramson,J.L.;Lewis,C.;Murrah,N.V.;Anderson,G.T.;Vaccarino,V.RelationofC-ReactiveProteinandTumorNecrosisFactor-AlphatoAmbulatoryBloodPressureVariabilityinHealthyAdults.Am.J.Cardiol.2006,98,649–652.[CrossRef]103.Simundic,A.-M.;Kackov,S.;Miler,M.;Fraser,C.G.;Petersen,P.H.TermsandSymbolsUsedinStudiesonBiologicalVariation:TheNeedforHarmonization.Clin.Chem.2015,61,438–439.[CrossRef]
	
	
Getulio José Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

Biomolecules2021,11,1464
17of17
104.Khuseyinova,N.;Greven,S.;Rückerl,R.;Trischler,G.;Loewel,H.;Peters,A.;

---

### Chunk 10/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891–1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista não identificada
**Section:** discussion | **Similarity:** 0.530

from125to250pg/ml,whileforthoseover75years,itextendsfrom125to500pg/ml.Itiscrucialtoconductathoroughevaluationofpatientswithinthegreyzone,consideringfactorssuchasobesity,race-basedvariations,andongoingtreatment(asmanypatientswithahistory
ofhypertensionmayalreadybeondiuretics,renin–angiotensin
systeminhibitors,ormineralocorticoidreceptorantagonists).Intheoutpatientsetting,theextentofelevationinNPconcen-trationsatthetimeofheartfailurediagnosisiscloselylinkedtothe
riskofsubsequenthospitalizationandmortality.16Asaresult,therehasbeenasuggestiontoutilizeNT-proBNPconcentrationsatthe
timeofacommunity-basedheartfailurediagnosisasatriagingtooltoprioritizeaccesstoexpediteddiagnosticechocardiogra-phyandtosetupafollow-upplanforindividualswiththehighest
short-termriskofadverseevents.Theauthorsofthisconsensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwi

---

### Chunk 11/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.527

N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmitralowvelocity;E′,earlydiastolicmitralannularvelocity;TAPSE,tricuspidannularplaneexcursion;PASP,pulmonaryarterialsystolicpressure;RVOT-AT,rightventricularoutowtractaccelerationtime;VO2peak,peakoxygenconsumption;NYHA,NewYorkHeartAssociation;AF,atrialbrillation;ACE-I,angiotensin-converting-enzymeinhibitors;ARBs,angiotensin-receptorblockers;MRA,mineralocorticoid-receptorantagonist;ICD,implantablecardioverter-debrillator;CRT,cardiacresynchronizationtherapy;IGF-1D,IGF-1deciency;DHEA-SD,DHEA-Sdeciency.

---

### Chunk 12/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.523

gnostics,andSingulex.All
otherauthorshavereportedthattheyhavenorelationshipsrelevanttothecontentsofthispapertodisclose.ManuscriptreceivedJuly11,2019;revisedmanuscriptreceivedJuly25,2019,acceptedJuly28,2019.JACCVOL.74,NO.16,2019Leeetal.OCTOBER22,2019:2032–43Sex-SpecicThresholdsofhs-cTnI2033

internationalguidelinesinuseduringenrollment(9,10).Throughoutthedurationofthetrial,allsitesmeasuredcardiactroponinusingboththecTnIand
hs-cTnIassayssimultaneously.Duringthevalidation
phase,onlytheresultsofthecTnIassaywerere-portedtotheattendingclinician,whileduringtheimplementationphase,onlytheresultsofthehs-cTnIassaywerereported.ThecTnIassay(ARCHITECTSTATtroponinIassay;AbbottLaboratories,AbbottPark,Illinois)with
asinglediagnosticthresholdforwomenandmen
wasusedtoguideclinicaldecisionsduringthevali-
dationphase.Theinterassaycoefcientofvariationwas<10%at40ng/lat7sitesand50ng/lat3sites,andtheseconcentrationswereusedasthediagnostic
thresholdsduringthevalidationphase(11).Duringtheimplementationphase,a

---

### Chunk 13/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.522

50%Moderate< 100< 2.6Low< 115< 3.0Alarming levels:Suspected homozygous familial hypercholesterolaemia:In untreated individuals> 500> 13.0In treated individuals> 300> 7.8Suspected heterozygous familial hypercholesterolaemia> 190> 4.9Unit conversion: [mg/dl] × 0.026 = [mmol/l].less, as with the use of other formulas, the accu-racy of non-HDL-C calculation depends on the bi-ological and analytical variability of TC and HDL-C concentrations. However, the biological variability 
of HDL-C levels is much lower than that of other lipid parameters, especially TG. In addition, HDL-C concentrations are much lower than the TC levels, which minimises their eﬀect on changes in calcu-lated non-HDL-C concentrations.Reporting of resultsAlongside the calculated non-HDL-C level, a laboratory report should include information on 

Arch Med Sci 2, March / 2024 369the desirable (target) values with regard to cardio-vascular risk (Table VI).

---

### Chunk 14/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.521

(mm/mmHg)0.63±0.290.53±0.220.68±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61±4.7018.89±4.9221.31±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31%)0.98III23(24.46%)7(23.33%)16(25.00%)0.87
IV5(5.33%)2(6.67%)3(4.69%)0.65Aetiology(ischaemic)27(28.7%)17(56.7%)10(15.6%)0.01Yearofdisease5[2–10.75]4[1–9.75]7[2.75–12]0.1AF11(22.4%)4(13.33%)7(10.90%)0.73
Beta-blockers66(91.7%)24(72.00%)42(65.60%)0.15
ACE-I31(43.1%)12(40.00%)19(29.70%)0.22ARBs26(36.1%)9(30.00%)17(26.60%)0.72MRA26(36.1%)8(26.70%)18(28.12%)0.88
ICD26(36.6%)8(26.66%)18(28.10%)0.88
CRT10(14.1%)1(3.33%)9(14.10%)0.15IGF-1D50(53.2%)16(53.3%)34(53.1%)0.98DHEA-SD73(77.7%)29(97.7%)44(68.7%)0.01
TypeIIdiabetes26(27.7%)6(20%)20(31.2)0.37Abbreviations:TD,testosteronedeciency;NTproBNP,N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmit

---

### Chunk 15/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891–1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista não identificada
**Section:** discussion | **Similarity:** 0.514

sensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwithamorethantwo-foldhigherriskofheartfailurehospitalizationand50%higherriskofmortalityascomparedwithanNT-proBNPof400–2000pg/ml.47Wesug-gestthat,irrespectiveofageandsex,patientswithanNT-proBNP
>2000pg/mlshouldbeprioritizedforechocardiographyandclini-calevaluationwithin2weeksofdiagnosis(Figure2).NT-proBNPinasymptomaticpatientswithriskfactors:heart
stressVariousriskfactors,suchashypertension,atheroscleroticcardio-vasculardisease,diabetes,obesity,andothers,contributetoanincreasedsusceptibilitytothedevelopmentofheartfailure.Intheabsenceofsymptomsofheartfailure,patientswithriskfactorsmay
exhibiteitherhearthealthorheartstress.Hearthealthrefersto
individualswhohaveastructurallynormalheartandnormalplasma
concentrationsofNPsandtroponins.©2023EuropeanSocietyofCardiology.

---

### Chunk 16/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.514

638(45)2,472(50)1,084(52)1,388(48)2,166(40)862(42)1,304(39)Calcium-channelblocker1,977(19)921(19)397(19)524(18)1,056(19)412(20)644(19)Nicorandil645(6)303(6)149(7)154(5)342(6)174(8)168(5)
Ivabradine146(1)68(1)25(1)43(1)78(1)33(1)45(1)
Spironolactone450(4)201(4)82(4)119(4)249(4)113(5)136(4)Electrocardiographicresults§Normal2,672(34)1,366(36)513(36)853(36)1,306(32)479(34)827(30)
Myocardialischemia2,510(32)1,023(27)342(24)681(28)1,487(36)445(32)1,042(38)ST-segmentelevation998(13)329(9)90(6)239(10)669(16)174(12)495(18)ST-segmentdepression1,328(17)583(16)226(16)357(15)745(18)234(17)511(18)
T-waveinversion1,277(16)640(17)252(17)388(16)637(15)232(16)405(15)Physiologicalparameters§Heartrate,beats/min8626882788278826842685258326Systolicbloodpressure,mmHg13929141301402914130137281362813728GRACEriskscore14338147361483414738140391393814040HematologicandclinicalchemistrymeasurementsHemoglobin,g/l13125125241242412623137251362513725eGFR,ml/min47164616471646164915491

---

### Chunk 17/30
**Article:** Hipertensão Arterial Sistêmica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.513

tensão Estágio 1:** 140-159 / 90-99 mmHg.
        *   **Hipertensão Estágio 2:** 160-179 / 100-109 mmHg.
        *   **Hipertensão Estágio 3:** ≥ 180/110 mmHg.
### 3. Tratamento Não Farmacológico: A Base da Terapia
*   **Princípio Fundamental:** A mudança no estilo de vida é recomendada para TODOS os estágios de pressão arterial, desde o diagnóstico.
*   **Principais Intervenções:**
    *   **Controle de Peso:** Cada 1 kg perdido reduz a PA em 1 mmHg.
    *   **Dieta Saudável:** Recomenda-se uma dieta anti-inflamatória e low-carb, que aborda a resistência insulínica. Pode reduzir a PA em 3-5 mmHg.
    *   **Atividade Física:** 150 minutos de atividade aeróbica/semana podem reduzir a PA em 5-7 mmHg.
    *   **Redução do Álcool:** Contribui para a diminuição da pressão.
    *   O potencial combinado dessas mudanças pode reduzir a pressão em 30 a 40 mmHg.
*   **A Polêmica do Sódio vs.

---

### Chunk 18/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.513

l/min/1.73 m2])Very high Cardiovascular disease documented clinically or by imaging examinations; diabetes mellitus with 
organ damage3 or other major risk factors4,5, early onset type 1 diabetes mellitus lasting > 20 years; chronic kidney disease with eGFR < 30 ml/min/1.73 m2; familial hypercholesterolaemia with cardiovas-cular disease or another major risk factor5; risk ≥ 10% and ≤ 20% according to Pol-SCORE/very high risk according to SCORE2 or SCORE-2-OP for gender and ageHighSigniﬁcantly elevated single risk factor, especially TC > 310 mg/dl (> 8 mmol/l), LDL-C > 190 mg/dl  (> 4.9 mmol/l), or blood pressure ≥ 180/110 mm Hg; familial hypercholesterolaemia without other risk factors; diabetes mellitus without organ damage (regardless of duration)6; chronic kidney disease with eGFR 3059 ml/min/1.73 m2; risk ≥ 5% and < 10% according to Pol-SCORE /high risk according to SCORE2 or SCORE-2-OP for gender and ageModerateRisk < 5% according to Pol-SCORE/low and moderate risk acc

---

### Chunk 19/30
**Article:** Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista não identificada
**Section:** introduction | **Similarity:** 0.511

ontraindicationsThefollowingcontraindicationsareinagreementwithaEuropeanWorkingGroup(Gianuzzi&
Tavazzi2001).�AcuteCHU(AMIorunstableangina),untilthe
conditionhasbeenstableforatleast5days�Dyspneaatrest�Pericarditis,myocarditis,endocarditis�Symptomaticaorticstenosis�Severehypertension.Thereisnoestablished,docu-
mentedborderlinebloodpressurevaluedeemedto
bethecut-offpointforincreasedrisk.Generallyit
isrecommendedthatdemandingphysicalexercise
beavoidedinthecaseofsystolicBP>180ordias-
tolicBP>105mmHg�Fever�Seriousnon-cardiacdiseaseHeartfailureBackgroundHeartfailureisaconditionwheretheheartisunabletopumpsufﬁcientlytomaintainbloodﬂowtomeetthemetabolicneedsoftheperipheraltissue(Braun-
wald&Libby,2008).Heartfailureisaclinicalsyn-
dromewithsymptomssuchasﬂuidretention,
breathlessness,orexcessivetirednesswhenrestingor
exercising,andwithobjectivesymptomsofreduced
systolicfunctionoftheleftventricleatrest.Asymptomaticleftventriculardysfunctionisoftentheprecursorofthissyndrome.Sympt

---

### Chunk 20/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.510

dline).Patientsaregroupedaccordingtowhethermyocardialinjurywaspresent(red)orabsent(gray).Pairedlog-ranktestresultsarep¼0.40forwomenwithmyocardialinjuryandp¼0.08forwomenwithoutmyocardialinjury.JACCVOL.74,NO.16,2019Leeetal.OCTOBER22,2019:2032–43Sex-SpecicThresholdsofhs-cTnI2039

infarctioninwomenandmen(15).Theimpactofsex-specicthresholdsonthediagnosisofmyocardialinfarctionhasbeenevaluatedinanumberofobser-vationalstudieswithdivergentndings(7,16–20).Mostofthesestudiesenrolledselectedpatientswith
acutecoronarysyndrome,ofwhomthemajoritywere
men.Furthermore,sex-specicthresholdswerenotusedtoguideclinicalcareorsubsequentinvestiga-
tionforcoronaryarterydisease.Here,weimple-
mentedsex-specicthresholdsintoroutineclinicalcareinarandomizedcontrolledtrialandevaluatedtheirimpactinconsecutivepatientspresentingwith
suspectedacutecoronarysyndrome.Wefoundthat
useofsex-specicthresholdsidentiedproportion-atelymorewomen,suchthattheoverallpercentages
ofwomenandmenidentiedashavingmyocardialinjury

---

### Chunk 21/30
**Article:** Hipertensão Arterial Sistêmica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.508

a PA sistólica em 5.6 mmHg e a diastólica em 2.8 mmHg. Potencializa o efeito de anti-hipertensivos. A forma taurato é a mais indicada.
*   **Cúrcuma Longa:** Uso por mais de 12 semanas mostrou redução média de 8 mmHg na PA sistólica.
*   **Outros:** Potássio (com cautela), quercetina, arginina, cacau, resveratrol e piquenogenol também podem auxiliar.
*   **Abordagem Integrativa:** A suplementação melhora vias metabólicas e inflamatórias, auxiliando no controle da pressão. É crucial saber quando usar medicação se as metas não forem atingidas apenas com estilo de vida e suplementos.
## ❓ Perguntas
- [Inserir Pergunta/Confusão]
## 📚 Tarefas
- [ ] 1. Para pacientes com suspeita de hipertensão, solicitar MAPA ou MRPA para um diagnóstico preciso.
- [ ] 2. Rastrear ativamente causas de hipertensão secundária, como apneia do sono (polissonografia) e disfunções da tireoide (TSH).
- [ ] 3.

---

### Chunk 22/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.507

ricanCollegeofCardiology/AmericanHeartAssociation
TaskForceonPracticeGuidelines.2013AHA/ACC
GuidelineonLifestyleManagementtoReduce
CardiovascularRisk.JAmCollCardiol.2014;63(25,ptB):2960-2984.doi:10.1016/j.jacc.2013.11.00323.YancyCW,JessupM,BozkurtB,etal;AmericanCollegeofCardiologyFoundation;AmericanHeart
AssociationTaskForceonPracticeGuidelines.2013
ACCF/AHAGuidelinefortheManagementofHeart
Failure.JAmCollCardiol.2013;62(16):e147-e239.doi:10.1016/j.jacc.2013.05.01924.O’GaraPT,KushnerFG,AscheimDD,etal.2013ACCF/AHAGuidelinefortheManagementof
ST-ElevationMyocardialInfarction:areportofthe
AmericanCollegeofCardiologyFoundation/
AmericanHeartAssociationTaskForceonPractice
Guidelines.JAmCollCardiol.2013;61(4):e78-e140.doi:10.1016/j.jacc.2012.11.01925.FihnSD,GardinJM,AbramsJ,etal;AmericanCollegeofCardiologyFoundation;AmericanHeart
AssociationTaskForceonPracticeGuidelines;AmericanCollegeofPhysicians;AmericanAssociationforThoracicSurgery;Preventive
CardiovascularNursesAssociation;Societyfor
Car

---

### Chunk 23/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.507

fortheman-
agementofheartfailure:Areportof
theAmericanCollegeofCardiologyFoundation/AmericanHeartAssociationtaskforceonpracticeguidelines.JAmCollCardiol.2013;62:e147–e239.3.BealeAL,MeyerP,MarwickTH,LamCSP,KayeDM.Sexdifferencesincardio-vascularpathophysiology:Whywomen
areoverrepresentedinheartfailurewith
preservedejectionfraction.Circulation.2018;138:198–205.4.ShahKS,XuH,MatsouakaRA,BhattDL,HeidenreichPA,HernandezAF,Devore
AD,YancyCW,FonarowGC.Heartfail-urewithpreserved,borderline,andre-ducedejectionfraction:5-yearout-
comes.JAmCollCardiol.2017;70:2476–2486.5.HsichEM,Grau-SepulvedaMV,HernandezAF,PetersonED,Schwamm
LH,BhattDL,FonarowGC.Sex
differencesinin-hospitalmortalityinacutedecompensatedheartfailurewithreducedandpreservedejection
fraction.AmHeartJ.2012;163:430–437.e3.6.CittadiniA,SalzanoA,IacovielloM,TriggianiV,RengoG,CacciatoreF,
MaielloC,LimongelliG,MasaroneD,
PerticoneF,CimellaroA,PerroneFilardiP,PaolilloS,ManciniA,VolterraniM,VrizO,CastelloR,PassantinoA,Campo
M,ModestiPA

---

### Chunk 24/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891–1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.506

ceptorantagonist;NT-proBNP,N-terminal
pro-B-typenatriureticpeptide;RASi,renin–angiotensinsysteminhibitor.thesecut-points,itisindicativeoflikelyheartfailure,andarrangingechocardiographywithin6weeksisadvised(Figure2).Complexcut-pointschemesthatincorporatemultiplecomor-biditiesinadditiontoagecanbetakenintoconsideration,especially
iftheycanbeintegratedintoelectronichealthrecordsthattrig-
geranalarmwhenNT-proBNPconcentrationsexceedspeciedthresholds.Theseshouldincludeage-andsex-specicNT-proBNPcut-pointsforthediagnosisofHFwithadjustmentsforrenal
dysfunction,atrialbrillationorutterincludingventricularrate
onthebaselinerestingelectrocardiogram(ECG)andbodymass
index(BMI).Table1showssuggestedNT-proBNPcut-offsstrat-iedbyageandgenderfornon-obesepatientswithoutkidneyfailureandatrialbrillation/utteronbaselineECG.46Thefol-lowingsuggestedmodicationsforcomorbidconditionsarebased
moreonexpertopinionratherthanonstrongevidenceandshould
berenedasmoreinformationbecomesavailable.WheneGFRis<30ml/min

---

### Chunk 25/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891–1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.505

calPracticeGuidelines.JAmCollCardiol2022;79:1757–1780.https://doi.org/10.1016/j.jacc.2021.12.0114.Revuelta-LópezE,BarallatJ,CserkóováA,Gálvez-MontónC,JaffeAS,JanuzziJL,etal.Pre-analyticalconsiderationsinbiomarkerresearch:Focusoncardiovasculardisease.ClinChemLabMed.2021;59:1747–1760.5.Pop-BusuiR,JanuzziJL,BruemmerD,ButaliaS,GreenJB,HortonWB,etal.Heartfailure:Anunderappreciatedcomplicationofdiabetes.Aconsensusreportofthe
AmericanDiabetesAssociation.DiabetesCare2022;45:1670–1690.https://doi.org/10.2337/dci22-00146.BozkurtB,CoatsAJS,TsutsuiH,AbdelhamidCM,AdamopoulosS,AlbertN,etal.Universaldenitionandclassicationofheartfailure:AreportoftheHeartFailureSocietyofAmerica,HeartFailureAssociationoftheEuropean
SocietyofCardiology,JapaneseHeartFailureSocietyandWritingCommittee
oftheUniversalDenitionofHeartFailure:EndorsedbytheCanadianHeart
FailureSociety,HeartFailureAssociationofIndia,CardiacSocietyofAustralia
andNewZealand,andChineseHeartFailureAssociation.EurJHeartFail2021;23:352–

---

### Chunk 26/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.504

heTaskForce
fortheDiagnosisandManagementofHypertrophic
CardiomyopathyoftheEuropeanSocietyof
Cardiology(ESC).EurHeartJ.2014;35(39):2733-2779.doi:10.1093/eurheartj/ehu28461.WarnesCA,WilliamsRG,BashoreTM,etal.ACC/AHA2008GuidelinesfortheManagementof
AdultsWithCongenitalHeartDisease:areportof
theAmericanCollegeofCardiology/AmericanHeart
AssociationTaskForceonPracticeGuidelines
(WritingCommitteetoDevelopGuidelinesonthe
ManagementofAdultsWithCongenitalHeart
Disease)developedincollaborationwiththe
AmericanSocietyofEchocardiography,Heart
RhythmSociety,InternationalSocietyforAdult
CongenitalHeartDisease,Societyfor
CardiovascularAngiographyandInterventions,
andSocietyofThoracicSurgeons.JAmCollCardiol.2008;52(23):e143-e263.doi:10.1016/j.jacc.2008.10.00162.MoscaL,BankaCL,BenjaminEJ,etal;ExpertPanel/WritingGroup;AmericanHeartAssociation;
AmericanAcademyofFamilyPhysicians;American
CollegeofObstetriciansandGynecologists;
AmericanCollegeofCardiologyFoundation;Society
ofThoracicSurgeons;AmericanMedicalW

---

### Chunk 27/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.502

enta online que usa parâmetros clínicos e o escore de cálcio para estimar o risco cardiovascular em 10 anos. Possui limitações por não incluir marcadores da medicina integrativa.
*   **Uso Criterioso de Estatinas:**
    - **Prevenção Primária (baixo risco):** O uso é controverso e muitas vezes desnecessário, pois o NNT é muito alto e os riscos de efeitos adversos podem superar os benefícios.
    - **Prevenção Secundária (pós-evento):** O uso é justificado pelo baixo NNT e pelos **efeitos pleotrópicos** da estatina, que incluem:
        - Redução da inflamação e melhora da função endotelial.
        - Diminuição da oxidação dentro da placa.
        - Estabilização da placa, tornando-a menos propensa à ruptura.
*   **Exames Clínicos Avançados:**
    - **Subfracionamento das partículas de LDL e HDL:** Avalia o tamanho e a quantidade das partículas.
    - **Anti-LDL Oxidado:** Mede a taxa de oxidação do colesterol.

---

### Chunk 28/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.501

±SDMean±SDMean±SDAge(years)66.18±10.2668.93±9.74564.89±10.3250.12NTproBNP(pg/ml)2597.05±4093.042794.47±3380.142504.52±4409.550.72
BSA(m2)1.70±0.161.68±0.11.71±0.190.34SBP(mmHg)123.29±17.82121.32±16.86124.24±18.370.53DBP(mmHg)75.46±12.3975.05±9.5175.65±13.650.85
eGFR(ml/min)68.61±34.2854.27±23.0275.55±36.760.001
Haemoglobin(g/dl)12.85±1.5312.50±1.2113.01±1.650.13Albumin(%)56.8±5.256.6±7.756.9±3.70.9Testosterone(ng/dl)48.80±61.8613.60±6.6362.55±68.16<0.001Ejectionfraction(%)33.81±6.4633.20±7.6634.10±5.850.53
LAVi(ml/m2)49.46±25.5755.51±30.2446.63±22.770.17e/E′14.68±9.9613.04±4.9512.53±6.400.16TAPSE(mm)18.82±4.5117.78±4.2619.31±4.560.12
PASP(mmHg)34.38±13.2537.69±13.7232.84±12.840.98
RVOT-AT(ms)103.27±36.47112.11±34.7497.15±37.730.35TAPSE/PASP(mm/mmHg)0.63±0.290.53±0.220.68±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61±4.7018.89±4.9221.31±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31

---

### Chunk 29/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891–1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.500

herauthorshavenothing
todisclose.References1.McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,BöhmM,etal.;ESCScienticDocumentGroup.2021ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure:DevelopedbytheTaskForcefor
thediagnosisandtreatmentofacuteandchronicheartfailureoftheEuropean
SocietyofCardiology(ESC).WiththespecialcontributionoftheHeartFailure
Association(HFA)oftheESC.EurJHeartFail2022;24:4–131.https://doi.org/10.1002/ejhf.23332.Guidelinesforthediagnosisofheartfailure.TheTaskForceonHeartFailureoftheEuropeanSocietyofCardiology.EurHeartJ1995;16:741–751.3.HeidenreichPA,BozkurtB,AguilarD,AllenLA,ByunJJ,ColvinMM,etal.AHA/ACC/HFSAGuidelineforthemanagementofheartfailure:Executive
summary:AreportoftheAmericanCollegeofCardiology/AmericanHeart
AssociationJointCommitteeonClinicalPracticeGuidelines.JAmCollCardiol2022;79:1757–1780.https://doi.org/10.1016/j.jacc.2021.12.0114.Revuelta-LópezE,BarallatJ,CserkóováA,Gálvez-MontónC,JaffeAS,JanuzziJL,etal.Pre-analyticalconsid

---

### Chunk 30/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.500

vida e identificar fatores de risco para inflamação e disfunção endotelial (dieta, estresse, sedentarismo).
- [ ] 2. Utilizar a calculadora MESA Risk para determinar o risco cardiovascular dos pacientes e considerar a solicitação do Escore de Cálcio Coronariano antes de prescrever estatinas em prevenção primária.
- [ ] 3. Ao avaliar o risco cardiovascular, solicitar exames avançados como a relação ApoB/ApoA, subpartículas de lipoproteínas e anti-LDL oxidado para uma análise mais aprofundada.
- [ ] 4. Em pacientes de prevenção primária, mesmo com colesterol alto, priorizar mudanças no estilo de vida antes de considerar o uso de estatinas.
- [ ] 5. Reservar o uso de estatinas principalmente para pacientes em prevenção secundária ou de altíssimo risco, focando nos seus efeitos pleotrópicos.
- [ ] 6.

---

